Condition: Non Small Cell Lung Cancer NSCLC · Sponsor: Peking University Cancer Hospital & Institute
The goal of phase Ib study was to evaluate efficacy and tolerability of the combination of vebreltinib and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer with c-met amplification after failure of EGFR-TKI treatment; to determine the maximum tolerated dose (MTD), and to evaluate the dose-limiting toxicity (DLT) and (recommended Phase 2 dose) RP2D of vebreltinib with furmonertinib. The goal of phase II study was to evaluate efficacy \[overall response rate (ORR), progression-free survival (PFS), and so on\] of vebreltinib and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer with c-met amplification after failure of EGFR-TKI treatment.
This description comes directly from the study's public registry record.
Minglei Zhuo · +86 88196456 · minglei1978@163.com
Always discuss trial participation with your own doctor first.
| Ordos Central Hospital | Neimeng, Neimeng, China | Not Yet Recruiting |
| Peking University Cancer Hospital (Inner Mongolia Campus) | Neimeng, Neimeng, China | Not Yet Recruiting |
| Affiliated Hospital of Hebei University | Baoding, China | Not Yet Recruiting |
| Baotou Cancer Hospital | Baotou, China | Recruiting |
| Peking University Cancer Hospital & Institute | Beijing, China | Recruiting |
| Beijing Chest Hospital, Capital Medical University | Beijing, China | Not Yet Recruiting |
| Beijing Daxing District People's Hospital | Beijing, China | Not Yet Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Not Yet Recruiting |
| Peking University People's Hospital | Beijing, China | Not Yet Recruiting |
| Peking University Third Hospital | Beijing, China | Not Yet Recruiting |
| The Second Hospital of Dalian Medical University | Dalian, China | Not Yet Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07087223